Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Meditation on Mechanism of Coronary Heart Disease
This study has been completed.
First Received: February 2, 2001   Last Updated: August 17, 2006   History of Changes
Sponsored by: National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00010738
  Purpose

To study the effects of Transcendental Meditation on Coronary Heart Disease


Condition Intervention Phase
Coronary Heart Disease
Procedure: Meditation
Phase II

Study Type: Interventional
Study Design: Treatment, Randomized
Official Title: Effects of Meditation on Mechanism of Coronary Heart Disease

Resource links provided by NLM:


Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment: 145
Study Start Date: September 1999
Estimated Study Completion Date: August 2002
Detailed Description:

Recent advances in our understanding of the pathophysiology of acute cardiac events - specifically, identification of the roles that arterial vasomotor dysfunction and autonomic nervous system imbalances play in the pathophysiologic cascade during such acute events - provides a platform for new mechanistic investigation of the interplay of psychosomatic stress and CHD (coronary heart disease). Preliminary evidence further suggests that Complementary and Alternative Medicine (CAM) practices, such as the Transcendental Meditation (TM) technique, can not only reduce stress but also reduce acute cardiac events in patients with CHD. Based on these and related data, we propose a randomized, blinded, controlled study of the effects of one CAM practice, the TM technique, compared to a control group, on the primary outcomes of (1) arterial vasomotor dysfunction (brachial artery reactivity); (2) autonomic nervous system imbalances (heart rate variability); (3) transient myocardial ischemia (ST-segment depression); and (4) the secondary outcomes of psychological stress and quality of life (anger, hostility, anxiety, depression, perceived health, disease-specific symptoms, and life stress/social resources).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to attend training sessions and meetings
  • Local residence

Exclusion Criteria:

  • Comorbid disease precluding survival in group
  • MI, unstable angina, CABG or PTCA within last three months.
  • Cognitive/psychological/substance abuse impairment
  • Atrial fibrillation, predominant pacemaker rhythm or significant conduction system disease
  • Significant valvular heart disease
  • Class III or IV heart failure
  • Renal failure
  • Participating in a formal stress management program
  • Participation in another trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00010738

Locations
United States, California
Preventive and Rehabilitative Cardiac Center
Los Angeles, California, United States
Sponsors and Collaborators
Investigators
Principal Investigator: C. Noel Bairey Merz, M.D. Preventive and Rehabilitative Cardiac Center
  More Information

No publications provided

Study ID Numbers: R01 AT000226-01M, R01 AT000226-01
Study First Received: February 2, 2001
Last Updated: August 17, 2006
ClinicalTrials.gov Identifier: NCT00010738     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Ischemia
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Cardiovascular Diseases
Arteriosclerosis
Coronary Artery Disease

ClinicalTrials.gov processed this record on July 02, 2009